Cargando…

Adverse events following immunization with typhoid conjugate vaccine in an outbreak setting in Hyderabad, Pakistan

Pakistan is facing the world's largest outbreak of extensively drug-resistant (XDR) Typhoid. Vaccination campaign for children aged 6 months to 10 years old with Typhoid Conjugate Vaccine (Typbar-TCV®) was conducted in high-risk areas of Hyderabad during 2018. About 207,000 children were vaccin...

Descripción completa

Detalles Bibliográficos
Autores principales: Qamar, Farah Naz, Yousafzai, Mohammad Tahir, Khaliq, Asif, Karim, Sultan, memon, Hina, Junejo, Amber, Baig, Inayat, Rahman, Najeeb, Bhurgry, Shafqat, Afroz, Hina, Sami, Uzma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7166079/
https://www.ncbi.nlm.nih.gov/pubmed/32201138
http://dx.doi.org/10.1016/j.vaccine.2020.03.028
_version_ 1783523501094731776
author Qamar, Farah Naz
Yousafzai, Mohammad Tahir
Khaliq, Asif
Karim, Sultan
memon, Hina
Junejo, Amber
Baig, Inayat
Rahman, Najeeb
Bhurgry, Shafqat
Afroz, Hina
Sami, Uzma
author_facet Qamar, Farah Naz
Yousafzai, Mohammad Tahir
Khaliq, Asif
Karim, Sultan
memon, Hina
Junejo, Amber
Baig, Inayat
Rahman, Najeeb
Bhurgry, Shafqat
Afroz, Hina
Sami, Uzma
author_sort Qamar, Farah Naz
collection PubMed
description Pakistan is facing the world's largest outbreak of extensively drug-resistant (XDR) Typhoid. Vaccination campaign for children aged 6 months to 10 years old with Typhoid Conjugate Vaccine (Typbar-TCV®) was conducted in high-risk areas of Hyderabad during 2018. About 207,000 children were vaccinated. Here we report the adverse events following immunization (AEFI) during the campaign. The campaign was carried out using outreach and fixed centre strategy. Community mobilizers visited each household to perform line listing and mobilize parents with age-eligible children. Children were observed for 30 min post-vaccination. Two-pronged strategy was used for ascertainment of AEFI. A 24/7 hotline number was provided to all parents/caretakers (n = 199,861) to report AEFI during 14 days following immunization. An age-stratified (n = 7139 children) were actively followed at days 7 and 14 for the ascertainment of AEFI. All AEFI were examined by three trained medical officers. A structured questionnaire using Brighton collaboration criteria with level 3 diagnostic certainty was used for the recording of AEFI. Data were analysed using Microsoft Excel Office 365. Overall, 499 AEFI (433 in the subset actively followed and 66 self-reported through hotline) were observed. The rate of AEFI was significantly higher among very young children (age group 6 to 12 months) as compared to 2 to 3 years old children (0.54% vs. 0.33% respectively; p-value < 0.001). Fever was the most common AEFI self-reported through the hotline (38/199,861 = 0.02%) and among the subset followed actively for 14 days (206/7139 = 2.89%). Fever was followed by local reactogenicity 10/199,861(0.01%), and 134/7139 (1.88%) through self-reported hotline and active follow-up, respectively. No serious AEFI was observed. Administration of a single dose of Typbar-TCV among children aged 6 months to 10 years old during an outbreak setting of Hyderabad Pakistan was safe.
format Online
Article
Text
id pubmed-7166079
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier Science
record_format MEDLINE/PubMed
spelling pubmed-71660792020-04-23 Adverse events following immunization with typhoid conjugate vaccine in an outbreak setting in Hyderabad, Pakistan Qamar, Farah Naz Yousafzai, Mohammad Tahir Khaliq, Asif Karim, Sultan memon, Hina Junejo, Amber Baig, Inayat Rahman, Najeeb Bhurgry, Shafqat Afroz, Hina Sami, Uzma Vaccine Article Pakistan is facing the world's largest outbreak of extensively drug-resistant (XDR) Typhoid. Vaccination campaign for children aged 6 months to 10 years old with Typhoid Conjugate Vaccine (Typbar-TCV®) was conducted in high-risk areas of Hyderabad during 2018. About 207,000 children were vaccinated. Here we report the adverse events following immunization (AEFI) during the campaign. The campaign was carried out using outreach and fixed centre strategy. Community mobilizers visited each household to perform line listing and mobilize parents with age-eligible children. Children were observed for 30 min post-vaccination. Two-pronged strategy was used for ascertainment of AEFI. A 24/7 hotline number was provided to all parents/caretakers (n = 199,861) to report AEFI during 14 days following immunization. An age-stratified (n = 7139 children) were actively followed at days 7 and 14 for the ascertainment of AEFI. All AEFI were examined by three trained medical officers. A structured questionnaire using Brighton collaboration criteria with level 3 diagnostic certainty was used for the recording of AEFI. Data were analysed using Microsoft Excel Office 365. Overall, 499 AEFI (433 in the subset actively followed and 66 self-reported through hotline) were observed. The rate of AEFI was significantly higher among very young children (age group 6 to 12 months) as compared to 2 to 3 years old children (0.54% vs. 0.33% respectively; p-value < 0.001). Fever was the most common AEFI self-reported through the hotline (38/199,861 = 0.02%) and among the subset followed actively for 14 days (206/7139 = 2.89%). Fever was followed by local reactogenicity 10/199,861(0.01%), and 134/7139 (1.88%) through self-reported hotline and active follow-up, respectively. No serious AEFI was observed. Administration of a single dose of Typbar-TCV among children aged 6 months to 10 years old during an outbreak setting of Hyderabad Pakistan was safe. Elsevier Science 2020-04-23 /pmc/articles/PMC7166079/ /pubmed/32201138 http://dx.doi.org/10.1016/j.vaccine.2020.03.028 Text en © 2020 The Author(s) http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Qamar, Farah Naz
Yousafzai, Mohammad Tahir
Khaliq, Asif
Karim, Sultan
memon, Hina
Junejo, Amber
Baig, Inayat
Rahman, Najeeb
Bhurgry, Shafqat
Afroz, Hina
Sami, Uzma
Adverse events following immunization with typhoid conjugate vaccine in an outbreak setting in Hyderabad, Pakistan
title Adverse events following immunization with typhoid conjugate vaccine in an outbreak setting in Hyderabad, Pakistan
title_full Adverse events following immunization with typhoid conjugate vaccine in an outbreak setting in Hyderabad, Pakistan
title_fullStr Adverse events following immunization with typhoid conjugate vaccine in an outbreak setting in Hyderabad, Pakistan
title_full_unstemmed Adverse events following immunization with typhoid conjugate vaccine in an outbreak setting in Hyderabad, Pakistan
title_short Adverse events following immunization with typhoid conjugate vaccine in an outbreak setting in Hyderabad, Pakistan
title_sort adverse events following immunization with typhoid conjugate vaccine in an outbreak setting in hyderabad, pakistan
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7166079/
https://www.ncbi.nlm.nih.gov/pubmed/32201138
http://dx.doi.org/10.1016/j.vaccine.2020.03.028
work_keys_str_mv AT qamarfarahnaz adverseeventsfollowingimmunizationwithtyphoidconjugatevaccineinanoutbreaksettinginhyderabadpakistan
AT yousafzaimohammadtahir adverseeventsfollowingimmunizationwithtyphoidconjugatevaccineinanoutbreaksettinginhyderabadpakistan
AT khaliqasif adverseeventsfollowingimmunizationwithtyphoidconjugatevaccineinanoutbreaksettinginhyderabadpakistan
AT karimsultan adverseeventsfollowingimmunizationwithtyphoidconjugatevaccineinanoutbreaksettinginhyderabadpakistan
AT memonhina adverseeventsfollowingimmunizationwithtyphoidconjugatevaccineinanoutbreaksettinginhyderabadpakistan
AT junejoamber adverseeventsfollowingimmunizationwithtyphoidconjugatevaccineinanoutbreaksettinginhyderabadpakistan
AT baiginayat adverseeventsfollowingimmunizationwithtyphoidconjugatevaccineinanoutbreaksettinginhyderabadpakistan
AT rahmannajeeb adverseeventsfollowingimmunizationwithtyphoidconjugatevaccineinanoutbreaksettinginhyderabadpakistan
AT bhurgryshafqat adverseeventsfollowingimmunizationwithtyphoidconjugatevaccineinanoutbreaksettinginhyderabadpakistan
AT afrozhina adverseeventsfollowingimmunizationwithtyphoidconjugatevaccineinanoutbreaksettinginhyderabadpakistan
AT samiuzma adverseeventsfollowingimmunizationwithtyphoidconjugatevaccineinanoutbreaksettinginhyderabadpakistan